Morningstar

Flagler Health Raises $50 Million in Series B Funding Round

Provided by Dow Jones

By Stephen Nakrosis 




   Musculoskeletal healthcare company Flagler Health said it raised $50 million in a Series B funding round, bringing the total amount of funds raised by the company to $63 million. 



  The funding round was led by Bessemer Venture Partners, and other participants included SignalFire, Alumni Ventures, and Tribeca Venture Partners, among others, the company said. 



  Flagler said its AI-native platform was trained on one of the largest musculoskeletal patient data sets and integrates directly into existing electronic medical records and workflow. The service has scaled to thousands of providers in over 36 states, the company said, adding 87% of patients report improvement in pain, mood, sleep, or mobility and reporting $164,000 in average additional annual revenue per provider. 





  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com 





  (END) Dow Jones Newswires



  August 11, 2026 15:41 ET (19:41 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
 
Plus, a deep dive on SpaceX’s bid to challenge US telecoms. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
What’s Ahead for Stocks This Quarter—and Where to Invest
 
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026. 
 
 
David Sekera, CFA, Preston Caldwell, and Susan Dziubinski 
 
 
 
Are TIPS ETFs the Best Way to Fight Inflation?
 
Plus, four TIPS ETFs with top marks from Morningstar, and what you need to know before investing. 
 
 
Daniel Sotiroff and Ivanna Hampton 
 
 
 
10 Best Blue-Chip Stocks to Buy for the Long Term
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
 
Even with significant growth potential, the stock’s lofty valuation is difficult to justify. 
 
 
Sean Dunlop, CFA 
 
 
 
 

			Sponsor Center